IRCT20181217042020N1已完成1 期
Evaluation of Tofacitinib efficacy for induction therapy in patients with Ulcerative Colitis
Digestive Disease Research Institute of Tehran University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Age> 18 years old
- •Known case of Ulcerative Colitis
- •Mayo score =6 in last 4 months
- •Rectal bleeding subscore of 1 to 3 in last 4 months
- •Endoscopic subscore of 2 or 3 in last 4 months
- •No clinical response or clinical remission (failed treatment) after ant TNF being used for at least 12- 14 weeks or Azathioporin used for at least 8-10 weeks
- •Unacceptable side effects after Corticostroid, Azathioprine, Mercaptopurine, Infliximab, or Adalimumab therapy
排除标准
- •1- Abnormal chest x ray
- •pregnant women or women who plan to become pregnant,
- •Acute infection
- •GFR< 60 ml/ min
- •Known case of cancer,
- •positive TB test (PPD/ or IGRA test)
- •Being positive for tests: HBV, HCV, HIV, CMV
研究者
相似试验
已完成
4 期
effectiveness of tofacitinib in moderate to severe ulcerative colitis compared to steroidCTRI/2023/09/057448Shankar Roy94
尚未招募
4 期
sefulness of tofacitinib in atopic dermatitisCTRI/2024/08/072026AIIMS Bhubaneswar
招募中
1 期
Effects of Tofacitinib on Ulcerative Colitis patientslcerative Colitis.Ulcerative colitisIRCT20181217042020N2Digestive Disease Research Institute of Tehran University of Medical Sciences40
招募中
3 期
Efficacy and safety of tofacitinib on clinical improvement in patients with COVID19COVID-19 pneumonia.Covid-19 diseaseU07.1IRCT20190804044429N7Mazandaran University of Medical Sciences240
招募中
3 期
Evaluation of the effect of Tofacitinib in covid-19 patientsIRCT20200531047619N1Iran University of Medical Sciences10